Introduction
============

COPD causes specific inflammatory cell types and structural changes in the airways that determine the severity of this condition. In Spain, chronic lung diseases were the fourth leading cause of mortality in 2008.[@b1-copd-10-2335] Furthermore, recent studies have reported that \~10.2% of Spanish population between 40 and 80 years have COPD,[@b2-copd-10-2335] but its under-diagnosis is frequent, and it is estimated that 73% of COPD cases have not been diagnosed.[@b3-copd-10-2335] These characteristics make COPD already a very costly condition, which is estimated to be equivalent to 0.2% of Spanish gross domestic product.[@b2-copd-10-2335]

Pharmacological treatment should adjust to each patient, guided by severity of symptoms, risk of exacerbations, and patient's response. Maintenance treatment of COPD relies on inhaled agents to control symptoms and/or complications of the disease and to prevent exacerbations.[@b1-copd-10-2335] Although these effects are required, inhaled pharmacological treatment depends on the efficacy of inhaler devices, patient's ability, and precision for using it;[@b4-copd-10-2335],[@b5-copd-10-2335] the reliability of devices for delivering the medicine directly to patients' lungs;[@b6-copd-10-2335],[@b7-copd-10-2335] and patient's compromise to comply timing, dosage, and frequency of medication taking.[@b8-copd-10-2335],[@b9-copd-10-2335] Suboptimal adherence within chronic conditions has been largely documented.[@b10-copd-10-2335],[@b11-copd-10-2335] Specifically, the lack of adherence toward medication regime can cause progression of COPD, more severity of symptoms and exacerbations, hospitalization, and detriment of the quality of life among COPD patients.[@b12-copd-10-2335]--[@b14-copd-10-2335] Medication adherence is a complex issue that can be defined as the degree to which a patient's medication-taking behavior and/or executing lifestyle changes correspond with agreed recommendations from a health care professional with respect to timing, dosage, and frequency.[@b8-copd-10-2335],[@b11-copd-10-2335] Over the last few years, researchers from several disciplines raised that adherence is an important problem given that is influenced not only by the increasingly complexity of lifelong therapy regimens but also by multiple clinical and nonclinical factors, to which we have to add the sociodemographic changes of a population aging.[@b15-copd-10-2335] These aspects represent a challenge for national health care systems worldwide that should be analyzed from a multidisciplinary perspective.[@b4-copd-10-2335],[@b6-copd-10-2335],[@b13-copd-10-2335],[@b14-copd-10-2335]

Although inhaled corticosteroids and long-acting β~2~-agonist (ICS/LABA) fixed-dose combinations (FDCs) have shown to relieve COPD symptoms similarly, recent research has shown that inhaler technique might affect adherence and hence efficacy of pharmacological treatment.[@b2-copd-10-2335]--[@b4-copd-10-2335] Inhaler technique is different between dry powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs). Each of the devices is associated with procedure, which is also affected by the ability of patients to handle it. The aim of this study was to examine medication adherence in COPD patients, focusing on the associations between adherence with COPD medication and inhaler devices, such as DPI and pMDI, while adjusting for the potential effect of the active ingredients. Moreover, some other factors that could be affecting medication adherence, such as clinical or socioeconomic characteristics of patients, were also analyzed.

Materials and methods
=====================

Study sample
------------

We conducted a retrospective and multicenter study based on a review of medical registries of COPD patients treated with ICS/LABA FDC, whose inhaler devices were either DPIs or pMDIs. Diagnosis was spirometry based, which was useful to classify patients into three categories: mild, moderate, and severe. Criteria were always the doctor's opinion. The study population included patients attending primary care centers, whose population was mostly urban, with a low-to-medium socioeconomic level.

The study sample comprised all COPD patients, who initiated their treatment with ICS/LABA FDC between January 1, 2007 and June 30, 2014. Moreover, patients fulfilled the following characteristics: 1) aged ≥35, 2) time of diagnosis \>3 years, and 3) were required to have registries with regular monitoring for 18 months (ie, those who were part of the long-term prescription program to obtain prescriptions with a confirmed record of the daily dosage, time interval, and duration of each treatment) (n=1,645). We excluded patients who were transferred outside the area, patients permanently institutionalized, patients who died during the period of analysis (n=382), and patients who presented clinical history of pulmonary emphysema, bronchiectasis, cystic fibrosis, and bronchial neoplasia.

Data source and variables
-------------------------

This retrospective study used integrated medical and pharmacy claims' data to identify the impact of inhaler technique toward adherence outcomes. Database contains information on COPD treatments with ICS/LABA FDC according to the Anatomical Therapeutic Chemical Classification System. We linked each treatment to its inhaler device, which could be a DPI or a pMDI. Thus, within DPIs were included Turbuhaler^®^, Accuhaler^®^, and NEXThaler^®^ that delivered formoterol/budesonide, salmeterol/fluticasone, and formoterol/beclomethasone, respectively. pMDIs delivered either formoterol/beclomethasone or salmeterol/fluticasone. Database is managed by Badalona Serveis Assitencials, which provides services to ten primary care centers, one hospital, and one sociohealth center. Ethics approval for the database to be used for research was granted by the Ethics Committee of the Hospital Universitari Germans Trías i Pujol.

Information on persistence was obtained for 1 year and half, indicating whether patient kept taking that treatment (persistence) at the third, sixth, 12th, and 18th months ([Figures 1](#f1-copd-10-2335){ref-type="fig"} and [2](#f2-copd-10-2335){ref-type="fig"}). Information on medication possession was also obtained by patient's refill count as well as data on duration by the number of days patient should be consuming the medication. Demographic characteristics of this sample were age, sex, and whether the patient was retired or not.

Furthermore, we gathered data of other potential confounders of medication adherence. A number of mild/moderate exacerbations and acute events, defined by the GesEPOC recommendations,[@b2-copd-10-2335] were collected. Medications, such as oral corticosteroids, systemic antibiotics, short-acting β~2~-agonist, short-acting anticholinergic, and systemic β~2~-agonists, to treat the symptoms and complications of COPD were available. Clinical data on comorbidities were included. Basically, it was indicated whether the patients suffered from simultaneous conditions, such as hypertension, diabetes, dyslipidemia, arthritis, osteoarthritis, depression, and dementia. Also severe events, including failures, ischemic heart disease, cerebrovascular diseases, and neoplasm, were indicated. Behavior attitudes that could derive to higher risk of developing a disease, for instance, obesity, smoking habit, and alcoholism, were also included as comorbidities. We had also access to number of visits to the physician during the period of study. Pharmacy administrative database also stores gross amount of pharmaceutical expenditure per patient. Data were adapted into our model by obtaining patient's average cost per month because Spanish patients have low co-payment levels for their medication; we approximated the potential cost that patients could face each month.

Calculation of patient's medication adherence
---------------------------------------------

To calculate adherence, we utilized the medication possession ratio (MPR), which is calculated by dividing the number of days supplied for a given medication by the number of days in the study, and persistence data.[@b16-copd-10-2335] Persistence is defined as the duration of time from initiation to discontinuation of therapy. Clinical outcomes are affected not only by how well patients take their medication but also by how long they take them, so the effect on how well patients take ICS/LABA FDC can be observed without being disturbed by discontinuation. First, we identified patients who last 18 months with their medication, which implied that they were persistent. These patients were analyzed to obtain adherence by using the MPR. Therefore, within these persistent patients, we applied a cut-point of 90% to the MPR. Since MPR tends to be overestimated,[@b9-copd-10-2335],[@b17-copd-10-2335] we also increased the limit to consider medication adherence. We had an ordered categorical variable, which showed to be very useful to identify persistence and adherence patterns: patients first need to be persistent with their treatment, and then they need to comply with their prescriptions.[@b4-copd-10-2335],[@b9-copd-10-2335] This variable reflects patients who are not neither persistent nor adherent, patients who are persistent but nonadherent, and patients who are persistent and showed adherence to their medication ([Figure 3](#f3-copd-10-2335){ref-type="fig"}). Finally, to check the robustness of our findings, we decided to use the most common cut-point that is 80% to the MPR.[@b13-copd-10-2335],[@b18-copd-10-2335] This analysis focuses on factors that diminish medication adherence.

Analysis
--------

To illustrate the distribution of patient's adherence within each medical device (DPI or pMDI), we tabulated sample characteristics for patients using either a DPI or a pMDI ([Table 1](#t1-copd-10-2335){ref-type="table"}). Univariate associations between medication adherence, medical device, and several confounders, such as age, comorbidities, exacerbations, severity of COPD, medication to treat COPD, and drug cost, were analyzed ([Table 2](#t2-copd-10-2335){ref-type="table"}). To perform basic analysis, we only included statistically significant variables from the univariate analysis into the first specification ([Table 3](#t3-copd-10-2335){ref-type="table"}).

With reference to health care utilization, visits to physicians were categorized in order to explore the association of having, on average, none or one visit per month, between one and three visits per month, and more than three visits per month (baseline will be none or one visit per month). We considered a variable for comorbidity status, which was categorized as having one, two, or more than three conditions, besides COPD.

Moreover, to consider the potential heterogeneity sources across age groups, the continuous variable age was split into five groups. Utilization of medication to treat COPD, besides ICS/LABA FDCs, was combined in a single variable that captures number of medication took per patient during the period of study. We did not analyze each pattern by itself because we are interested on adherence patterns in patients attempting to take ICS/LABA FDC chronically. [Tables 2](#t2-copd-10-2335){ref-type="table"}[](#t3-copd-10-2335){ref-type="table"}--[4](#t4-copd-10-2335){ref-type="table"} contain results expressed in percentage points (pp) and odd ratios.

Results
=======

Clinical and demographic characteristics
----------------------------------------

Persistence rates were diminishing throughout 18 months and were similar among inhaler devices at the 18th month ([Figures 1](#f1-copd-10-2335){ref-type="fig"} and [2](#f2-copd-10-2335){ref-type="fig"}). We could identify the final proportion of adherent patients on the basis of methodology described in the "Calculation of patient's medication adherence" section. Remarkably higher rates of discontinuation were observed in patients using a DPI. However, patients who have medication adherence were similar in both groups ([Figure 3](#f3-copd-10-2335){ref-type="fig"}). Sociodemographic and clinical characteristics of 1,263 COPD patients tabulated by an inhaler device are shown in [Table 1](#t1-copd-10-2335){ref-type="table"}. A total of 38.95% of patients used a pMDI and 61.05% used a DPI during the time of study. The mean age of patients was 71 years, most of them were retired (88.44%), and 83.45% of them were men. Time since diagnosis (in years) was similar in both groups. The most frequent comorbidity observed in this sample was hypertension (60.1%), followed by dyslipidemia (50.75%), which were very similar in both groups. Patients with moderate COPD represent 79.65%, and the distribution of disease severity is very similar across clusters. It is worth mentioning that the use of ICS/LABA FCD in COPD subjects is limited to severe or moderate-to-severe obstruction and common exacerbations; however, we observed patients classified as mild who use these therapies. Furthermore, one DPI included does not have indication for COPD in Spain but our sample shows that currently is being used with such a propose, which might be explained by a certain freedom to prescribe off-label. Almost half of the patients (40.79%) experienced at least one exacerbation.

[Table 2](#t2-copd-10-2335){ref-type="table"} contains results of univariate regressions. DPI utilization was negatively correlated with adherence; on the contrary, the effect of active ingredients was not statistically significant. Clinical characteristics, such as COPD severity, time since diagnosis, number of mild and moderate exacerbations, and some comorbidities, such as smoking and cerebrovascular diseases, were negatively correlated with adherence, except for moderate exacerbations that were positively correlated with it. None of the diseases that are mobility limiting were significant. Long-acting anticholin-ergic agents were positively correlated with adherence as well as most of the medication to treat COPD, except for systemic administration of β~2~-adrenoceptor agonists that were not statically significant. Pharmaceutical costs were negatively correlated with adherence, and visits to physician were positively correlated with it.

Inhaler technique and other confounders affecting patient's adherence to the COPD treatment
-------------------------------------------------------------------------------------------

Results are shown in [Table 3](#t3-copd-10-2335){ref-type="table"} with and without active ingredient variable. Remarkably, variable for inhaler devices increased its significance (*P*\<0.001), and the probability of adherence by a patient using a DPI would be diminished by almost 10 pp compared to that of a patient using pressurized inhalers. These measures were adjusted for confounders, and some of them were significant. For instance, time since diagnosis is negatively associated with medication adherence. In case of moderate exacerbations, the link is positive. Regarding health care resources, the coefficient of pharmaceutical cost would have a small negative impact on medication adherence, while the effect of doctor's visit is positive.

In [Table 4](#t4-copd-10-2335){ref-type="table"}, we present the results of the regression that provided the adjusted measures of association between the inhaler technique and medication adherence and showed to fit the data better than previous models. This analysis revealed that patients treated with ICS/LABA FDC delivered by a DPI were less likely to adhere to their COPD treatment compared to patients that used a pMDI. By contrast, the variable that captures the association between ICS/LABA and adherence was not significant. Regarding disease severity, worsening of COPD is not negatively associated with adherence. This effect is not consistent with the coefficient of time since the diagnosis, which implies that the probability of medication adherence would decrease by 0.7 pp, for an extra year with COPD.

The categorical variable for the number of comorbidities shows that having more than three multiple conditions would impact negatively on medication adherence, despite most of the comorbidities in the previous regressions were not statistically significant. Regarding comorbidities, we found that hypertension was positively correlated with adherence as well as smoking. Regarding patients' characteristics, age appeared to be determinant, affecting adherence to treatment negatively. However, this effect becomes smaller as we moved to older age groups.

An additional acute exacerbation for COPD patients was negatively associated with medication adherence, but number of medication to treat COPD, besides ICS/LABA FDC, showed to be not significant. An additional visit to the doctor was positively associated with medication adherence. Conversely, more than one physician visit per month is negatively associated with adherence. Some other potential confounders, such as sex, concomitant medication, and moderate exacerbations, were not statistically significant for explaining adherence with COPD medication. Additionally, results of the interaction term of sex and smoking suggest that the probability of medication adherence was reduced for smoking men compared to smoking women and nonsmokers. Regarding health care resources, cost was not significant. Robustness check confirmed our results, and the effect of inhaler technique increases its significance toward suboptimal adherence (*P*\<0.001).

Discussion
==========

These analyses revealed that after adjustment for confounding variables, especially the active agents, patients treated with ICS/LABA FCD delivered using a DPI (Accuhaler^®^, NEXThaler^®^, and Turbuhaler^®^) were less likely to show adherence compared to patients treated with ICS/LABA FCD delivered using a pMDI. Results are striking because, despite the inclusion of several confounders of adherence, there was still a statistically significant coefficient of the variable of inhaler devices' utilization, suggesting that factors related only to inhaler devices might weaken probability of medication adherence. We can find critical errors of DPIs in the literature. The most frequently reported flaw is failure to exhale before inhaling and in consequence, failure to use a forceful and deep inhalation.[@b19-copd-10-2335] Moreover, DPIs included in our analysis present errors regarding the metering of the dose and positioning the inhaler.[@b19-copd-10-2335] Suboptimal adherence limits the efficacy of inhalation therapy, since there are negative impacts in outcomes as survival and cost as well as clinical outcomes.[@b20-copd-10-2335],[@b21-copd-10-2335] Although there is not an agreement on the situation that predisposes to inhaler misuse, the identification of associations between inhaler technique and patients' adherence shed some light on reasons why suboptimal adherence has become a major problem.[@b3-copd-10-2335],[@b18-copd-10-2335],[@b22-copd-10-2335],[@b23-copd-10-2335]

Our results are consistent with the previous analyses that described several factors affecting medication adherence negatively.[@b8-copd-10-2335],[@b24-copd-10-2335],[@b25-copd-10-2335] In our analysis, we identified factors that affect adherence of long-term inhalation therapy in COPD patients. Age was negatively associated with adherence.[@b26-copd-10-2335] This effect is consistent with time since diagnosis, which indicates a negative in adherence as time passes toward adherence to long-term therapy. However, the effect decreases along with age.[@b27-copd-10-2335],[@b28-copd-10-2335] Hypertension patients were more likely to medication adherence, which is plausible because these patients might be also more controlled due to high blood pressure, and adherence in hypertension is higher compared to COPD, which could also influence adherence for COPD.[@b29-copd-10-2335] Conversely, arthritis and osteoarthritis have not shown to be statistically significant, although these conditions contribute to an inability of device utilization.[@b30-copd-10-2335] These results are likely to be explained by the constrained subsample size of these comorbidities; hence, further research is needed in this area.

Some patients failed to comply with physician's recommendations since they did not quit smoking (19% of the sample). Smoking cessation is the most effective way of slowing the progression of this disease.[@b12-copd-10-2335] Therefore, it is plausible to think that patients are also nonadherent to their medication.[@b31-copd-10-2335] Indeed, our results suggest that the smoking men's probability of medication adherence decreased by 30 pp. Although sex was not crucial for explaining adherence, the negative effect of the interaction term between smoking status and men is considerable. The sample was mostly composed of men, who represent the common COPD patient.[@b2-copd-10-2335] However, this pattern is changing since incidence of smoking, main cause of COPD, has increased in women, which have now greater health risks.[@b2-copd-10-2335]

Regarding health care utilization, we identified two effects of visiting the doctor. The effect of doctor visit would increase the probability of medication adherence.[@b18-copd-10-2335] Conversely, patients who have visited their doctor more than three times per month were more likely to have suboptimal adherence. Results are feasible since health care professional interventions are consistently positive for adherence and compliance.[@b32-copd-10-2335] However, many visits to the doctor negatively associated might indicate serious problems and patients are pushed to visit several times their physician.[@b14-copd-10-2335],[@b15-copd-10-2335],[@b33-copd-10-2335] Cost was not finally statistically significant toward adherence. This is plausible since Spanish patients do not bear 100% of the pharmaceutical costs directly.[@b34-copd-10-2335]

These results should be interpreted within the context of study limitations. First, this is a retrospective study, which is vulnerable to bias. For instance, we could identify endogeneity in results for exacerbations, since it is likely that the causal direction goes from medication adherence toward exacerbations and not vice versa.[@b13-copd-10-2335],[@b35-copd-10-2335] Second, this study was conducted in a single health system; thus, results may not be extrapolate to other populations. However, trends are similar to previous research.[@b17-copd-10-2335],[@b20-copd-10-2335],[@b23-copd-10-2335] Third, the assumption that obtaining prescription was equivalent to taking the medication, which might not be completely true. Moreover, our study approach to quantify adherence was done by using the MPR, which has been reported to be biased upward by previous research.[@b9-copd-10-2335],[@b14-copd-10-2335] Nevertheless, we tried to correct this by elevating the cut-point, so fewer patients would be seen as adherent, and testing robustness of estimates due to this cut-point confirmed our findings. Actually since we obtain the persistence to COPD long-term medication, our estimates could be more accurate than those of few others who also used MPR without taking into account persistence. It is also true that tracking adherence patterns may imply to have data across time, which can be accomplished by analyzing adherence prospectively as well as analyzing other issues related with poor adherence that were not measured, such as intentional and nonintentional nonadherences, patients' preferences, and specific steps that the patients fail to complete within the process of taking their medicine.[@b5-copd-10-2335],[@b36-copd-10-2335],[@b37-copd-10-2335] The fact that NEXThaler^®^ was introduced in 2012 could limit our study, but dataset provides a sufficient number of cases using NEXThaler^®^ in order to be included within the DPI group. Finally, we could not obtain some patients' characteristics, such as race, level of education, type of job, and few others. This problem of data limitation also restricts our outcomes.

Conclusion
==========

Medication adherence in COPD is crucial for optimizing clinical outcomes, and there are several factors that condition it. Inhaler devices are expected to help optimization of active ingredients. However, we found that DPIs included in our analysis (Turbuhaler^®^, Accuhaler^®^, and NEXThaler^®^) delivering ICS/LABA FDCs had a negative effect on patients' medication adherence compared to pMDIs. The findings reviewed here suggest that the pharmacological effectiveness of the FDC, which seemed to be very promising in the beginning, might be conditioned by the inhaler technique associated with inhaler devices. The special feature of our findings is that we adjusted for the effects of the active ingredients in order to explore the specific effect of inhaler technique toward adherence. We have also corroborated that patients' clinic and demographic characteristics are associated with adherence.

Suboptimal adherence is a major problem in long-term therapies, such as COPD treatment. The consideration of incidence trends and risk factors related to COPD, in addition to the aging of population, makes very relevant to overcome barriers to treatment adherence in order to avoid progression of the disease and waste of resources because patients cannot obtain the maximum efficacy of their treatment, even among those who want to take their medicine correctly. Overcoming barriers passes through the innovation of inhaler devices. Instead of attributing all the responsibility of poor utilization due to human errors, more intuitive and simple designs are needed.
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###### 

Characteristics of COPD patients according to the type of inhaler device: DPI or pMDI

  Characteristics                                                                  pMDI (n=492)          DPI (n=771)       Total (n=1,263)   *P*-value
  -------------------------------------------------------------------------------- --------------------- ----------------- ----------------- -----------
  Male (%)                                                                         38.95                 61.04             83.45             0.735
  Age, mean (SD) (years)                                                           70.54 (10.37)         70.66 (9.91)      70.61             0.326
   39--50                                                                          5.28                  3.50              4.20              --
   51--61                                                                          12.40                 13.75             13.22             --
   62--71                                                                          33.54                 32.68             33.02             --
   72--83                                                                          40.04                 40.73             40.46             --
   84--97                                                                          8.74                  9.34              9.11              --
  Retired status (%)                                                               87.2                  89.23             88.44             0.966
  Time since COPD was diagnosed, mean (SD) (years)                                 15.0 (5.19)           15.44 (5.04)      15.38 (5.10)      0.994
  Severity of COPD (%)                                                                                                                       
   Mild                                                                            17.89                 14.79             15.99             --
   Moderate                                                                        77.85                 80.80             79.65             --
   Severe                                                                          4.27                  4.41              4.35              --
  FEV~1~, mean (SD)                                                                76.6 (9.9)            79.1 (9.9)        79.2 (9.9)        0.256
  ICS/LABA FDC (%)                                                                                                                           
   Formoterol/beclomethasone                                                       24.59                 17.12             20.03             --
   Formoterol/budesonide                                                           0.0                   51.88             31.67             --
   Salmeterol/fluticasone                                                          75.41                 31.00             48.30             --
  Exacerbations (%) (binary on whether patients suffered an exacerbation or not)   36.99                 42.15             40.14             0.068
   Moderate                                                                        31.5                  36.96             34.84             \<0.001
   Acute                                                                           16.06                 14.92             15.36             0.630
  Comorbidities (%)                                                                                                                          
   Obesity                                                                         38.62                 40.86             39.98             0.650
   Smoking                                                                         21.14                 19.58             20.19             0.743
   Alcoholism                                                                      6.91                  6.10              6.41              0.891
   Cerebrovascular disease                                                         34.15                 35.80             35.15             0.948
   Hypertension                                                                    59.35                 60.57             60.10             0.650
   Diabetes                                                                        28.66                 28.40             28.50             0.732
   Dyslipidemia                                                                    52.44                 49.68             50.75             0.518
   Osteoarthritis                                                                  8.40                  6.28              7.17              0.099
   Arthritis                                                                       20.42                 21.16             20.73             0.714
   Stroke                                                                          23.78                 25.42             24.78             0.510
   Ischemic heart disease                                                          16.06                 15.30             15.60             0.948
   Failures                                                                        25.20                 27.11             26.37             0.987
   Dementia                                                                        6.50                  6.87              6.73              0.964
   Depression                                                                      24.19                 26.72             25.73             0.855
   Neoplasm                                                                        16.26                 17.12             16.79             0.846
  Other medication to treat COPD (%)                                               84.76                 84.95             84.88             --
   Oral corticosteroids                                                            8.54                  8.17              8.31              0.856
   Systemic antibiotics                                                            2.7                   7.0               5.9               \<0.05
   SABA                                                                            80.3                  80.4              80.3              0.862
   Short-acting anticholinergic                                                    57.72                 55.12             56.14             0.364
  Number of visits to doctor, mean (SD)                                            18.99 (13.28)         21.99 (14.24)     20.82 (13.94)     \<0.001
  Average cost per month, mean (SD) (Euros)                                        64.95 (43.54)         62.75 (44.10)     63.60 (43.88)     0.3852
  Mean of total health care cost per patient, mean (SD) (Euros)                    1,920.99 (1,427.22)   2,013 (1,716.5)   1,977 (1,716.5)   0.3527

**Note:** Patients' characteristics who visited their primary care center between January 2007 and June 2014.

**Abbreviations:** DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; SD, standard deviation; FEV~1~, forced expiratory volume in 1 second; ICS/LABA, inhaled corticosteroids and long-acting β~2~-agonist; FDC, fixed-dose combination; COPD, chronic obstructive pulmonary disease; SABA, short-acting β~2~-agonist.

###### 

Univariate analysis of each potential confounders of adherence

  Explanatory variables                                          Category                       Adherence (n=1,263)                           
  -------------------------------------------------------------- ------------------------------ --------------------- ------- --------------- -------
  Medical device DPI (baseline pMDI)                                                            −7.85                 0.72    0.583--0.8686   0.002
  ICS/LABA FDC (baseline formoterol/beclometasone)               Formoterol/budesonide          −3.58                 0.858   0.640--1.150    0.308
                                                                 Salmeterol/fluticasone         2.98                  1.13    0.860--1.487    0.378
  Therapy line (baseline first line)                             Second line                    16.55                 1.96    1.363--2.814    0.000
                                                                 Third line                     24.75                 2.75    1.222--6.186    0.011
  Age                                                                                           −0.35                 0.98    0.975--0.995    0.004
  Sex (baseline men)                                                                            6.29                  1.30    0.985--1.715    0.063
  Retired status                                                                                −3.14                 0.87    0.638--1.204    0.417
  Obesity                                                                                       4.61                  1.21    0.985--1.493    0.069
  Smoking                                                                                       7.63                  1.37    1.066--1.777    0.014
  Stroke                                                                                        −6.73                 0.75    0.594--0.957    0.020
  Cerebrovascular disease                                                                       −6.72                 0.75    0.608--0.935    0.010
  Hypertension                                                                                  0.89                  1.04    0.843--1.278    0.724
  Diabetes                                                                                      −1.80                 0.93    0.738--1.164    0.517
  Dislipemia                                                                                    −1.89                 0.92    0.753--1.133    0.448
  Osteoarthritis                                                                                0.87                  1.03    0.808--1.330    0.775
  Arthritis                                                                                     −0.31                 0.98    0.654--1.489    0.951
  Alcoholism                                                                                    6.51                  1.31    0.863--1.993    0.203
  Ischemic cardiomyopathy                                                                       −0.83                 0.96    0.730--1.277    0.807
  Failures                                                                                      2.89                  1.12    0.895--1.421    0.306
  Dementia                                                                                      −9.18                 0.68    0.446--1.309    0.075
  Depression                                                                                    −2.07                 0.92    0.727--1.156    0.465
  Neoplasm                                                                                      3.93                  1.17    0.896--1.548    0.239
  Number of exacerbations                                                                       4.48                  1.21    1.114--1.311    0.000
  Number of severe exacerbations                                                                −9.41                 0.91    0.684--1.210    0.518
  Number of mild/moderate exacerbations                                                         5.77                  1.28    1.165--1.403    0.000
  Severity of COPD (baseline mild)                               Moderate                       4.80                  1.23    0.930--1.619    0.148
                                                                 Severe                         22.15                 2.47    1.374--4.459    0.003
  Time since COPD was diagnosed Other medication to treat COPD                                  −1.72                 0.93    0.909--0.947    0.000
                                                                                                5.66                  1.27    1.181--1.375    0.000
                                                                 Oral corticosteroids           11.32                 1.61    1.307--1.990    0.000
                                                                 Systemic antibiotics           14.83                 1.87    1.444--2.430    0.000
                                                                 SABA                           16.95                 2.06    1.629--2.604    0.000
                                                                 Short acting anticholinergic   7.83                  1.388   1.130--1.707    0.002
                                                                 Β~2~ Agonists (systemic)       6.82                  1.33    0.903--1.956    0.149
  Long acting anticholinergic agents                                                            13.56                 1.77    1.393--2.260    0.000
  Cost                                                                                          −0.25                 0.98    0.986--0.991    0.000
  Visits to doctor                                                                              0.41                  1.017   1.009--1.25     0.000

**Abbreviations:** CI, confidence interval; DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; ICS/LABA, inhaled corticosteroids and long-acting β~2~-agonist; FDC, fixed-dose combination; COPD, chronic obstructive pulmonary disease; SABA, short-acting β~2~-agonist.

###### 

Multivariate results of potential confounders of adherence

  Explanatory variables (McFadden's *R*^2^=0.0711)   Adherence (n=1,263)                                                                                                                                                                                                                        
  -------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------ -------------- ------------------------------------------------------ ------------------------------------------------------ ----------------
  Medical device DPI (baseline pMDI)                 −9.95[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     0.60[\*](#tfn4-copd-10-2335){ref-type="table-fn"}      0.481--0.750   −9.57[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     0.61[\*](#tfn4-copd-10-2335){ref-type="table-fn"}      0.467--0.802
  ICS/LABA FDC (baseline formoterol/beclometasone)                                                                                                                                                                                                                                              
   Formoterol/budesonide                             --                                                     --                                                     --             2.07                                                   1.11                                                   0.798--1.556
   Salmeterol/fluticasone                            --                                                     --                                                     --             3.37                                                   1.19                                                   0.893--1.586
  Severity of COPD (baseline mild)                                                                                                                                                                                                                                                              
   Persistent moderate                               11.22[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     1.91[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}    1.323--2.766   11.65[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     1.89[\*](#tfn4-copd-10-2335){ref-type="table-fn"}      1.311--2.741
   Persistent severe                                 7.08                                                   1.49                                                   0.645--3.484   6.74                                                   1.47                                                   0.632--3.426
  Time since COPD was diagnosed                      −1.15[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     0.942                                                  0.917--0.968   −1.14[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     0.94[\*](#tfn4-copd-10-2335){ref-type="table-fn"}      0.918--0.968
  Therapy line                                                                                                                                                                                                                                                                                  
   Second                                            10.13[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.637[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.125--2.380   10.21[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.64[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}    1.130 -- 2.390
   Third                                             20.45[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   2.624[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.077--6.361   20.14[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   2.58[\*](#tfn4-copd-10-2335){ref-type="table-fn"}      1.063--6.305
  Age                                                −0.11                                                  0.994                                                  0.979--1.009   −0.12                                                  0.99                                                   0.978--1.009
  Sex                                                4.02                                                   1.23                                                   0.161--0.921   0.41                                                   1.23                                                   0.923--1.644
  Obesity                                            2.12                                                   1.11                                                   0.894--1.391   1.94                                                   1.10                                                   0.885--1.379
  Smoking                                            4.63                                                   1.268                                                  0.958--1.677   4.50                                                   1.260                                                  0.952--1.667
  Stroke                                             −3.34                                                  0.842                                                  0.588--1.206   −3.21                                                  0.848                                                  0.592--1.214
  Cerebrovascular disease                            −3.84                                                  0.821                                                  0.551--1.222   −3.85                                                  0.821                                                  0.551--1.222
  Exacerbations                                      −6.20[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   0.72[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}    0.529--1.001   −6.57[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   0.714[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   0.517--0.984
   Mild/moderate exacerbations                       10.22[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.69[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}    1.188--2.400   10.62[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.72[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}    1.210--2.457
  Long-acting anticholinergic agent                  2.77                                                   1.15                                                   0.838--1.584   2.73                                                   1.150                                                  0.836--1.582
  Pharmacological cost                               −0.21[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     0.989[\*](#tfn4-copd-10-2335){ref-type="table-fn"}     0.986--0.992   −0.21[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   0.989[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   0.986--0.992
  Visits to doctor                                   0.24[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}    1.012[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.004--1.021   0.24[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}    1.012[\*\*](#tfn5-copd-10-2335){ref-type="table-fn"}   1.004--1.021

**Notes:**

*P*\<0.001 and

*P*\<0.05.

**Abbreviations:** CI, confidence interval; DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; ICS/LABA, inhaled corticosteroids and long-acting β~2~-agonist; FDC, fixed-dose combination; COPD, chronic obstructive pulmonary disease.

###### 

Final specification: results of multivariable analysis examining the associations between inhaler devices for ICS/LABA FDC and adherence

  Explanatory variables (McFadden's *R*^2^=0.2898)    Adherence (n=1,263)                                                                                             
  --------------------------------------------------- ------------------------------------------------------- ------------------------------------------------------- --------------
  Medical device DPI (baseline pMDI)                  −5.38[\*](#tfn7-copd-10-2335){ref-type="table-fn"}      0.71[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       0.521--0.970
  ICS/LABA FDC (baseline formoterol/beclomethasone)                                                                                                                   
   Formoterol/budesonide                              −0.38                                                   0.97                                                    0.661--1.440
   Salmeterol/fluticasone                             3.07                                                    0.72                                                    0.241--2.174
  Severity of COPD (baseline moderate)                                                                                                                                
   Mild                                               −9.81[\*](#tfn7-copd-10-2335){ref-type="table-fn"}      0.53[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       0.300--0.960
   Severe                                             −5.15                                                   0.72                                                    0.241--2.174
  Time since COPD was diagnosed                       −0.78[\*](#tfn7-copd-10-2335){ref-type="table-fn"}      0.95[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       0.923--0.981
  Therapy line (baseline first line)                                                                                                                                  
   Second line                                        −1.27                                                   0.92                                                    0.603--1.413
   Third line                                         1.69                                                    1.11                                                    0.437--2.823
  Sex (baseline men)                                  3.01                                                    1.21                                                    0.816--1.782
  Age (as a continuous variable)                      −1.23[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}    0.96[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}     0.887--0.966
  Age groups (baseline 87--97)                                                                                                                                        
   39--51                                             −34.04[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.99[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       0.169--0.578
   51--61                                             −29.69[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.13[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       0.036--0.501
   61--71                                             −23.04[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.212[\*](#tfn7-copd-10-2335){ref-type="table-fn"}      0.081--0.552
   72--83                                             −16.62[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.32[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}     0.173--0.599
  Retired status                                      5.05                                                    1.37                                                    0.736--2.563
  Number of comorbidities                                                                                                                                             
   2                                                  −0.74                                                   0.95                                                    0.662--1.374
   3                                                  −10.96[\*](#tfn7-copd-10-2335){ref-type="table-fn"}     0.49[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       0.282--0.864
  Obesity                                             6.26                                                    1.47                                                    0.975--2.231
  Smoking                                             14.52[\*](#tfn7-copd-10-2335){ref-type="table-fn"}      2.248[\*](#tfn7-copd-10-2335){ref-type="table-fn"}      1.105--5.587
  Smoking men                                         −28.73[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.167[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}    0.034--0.800
  Hypertension                                        6.29[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       1.48[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       1.085--2.018
  Diabetes                                            5.00                                                    1.36                                                    0.981--1.902
  Acute exacerbation                                  −8.36[\*](#tfn7-copd-10-2335){ref-type="table-fn"}      0.59[\*](#tfn7-copd-10-2335){ref-type="table-fn"}       0.378--0.933
  Moderate exacerbation                               2.20                                                    1.14                                                    0.914--1.438
  Long-acting anticholinergic agents                  5.23                                                    1.37                                                    0.928--2.050
  Other medication to treat COPD                      2.44                                                    1.16                                                    0.995--1.362
  Additional visit to the doctor Visits to doctor     2.15[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}     1.14[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}     1.122--1.165
   Two times per month (on average)                   −33.88[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.11[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}     0.797--0.165
   Three times per month (on average)                 −67.25[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.0028[\*\*](#tfn8-copd-10-2335){ref-type="table-fn"}   0.009--0.007
  Average pharmacological cost per month              0.04                                                    1.00                                                    0.999--1.006

**Notes:**

*P*\<0.05 and

*P*\<0.001.

**Abbreviations:** ICS/LABA, inhaled corticosteroids and long-acting β~2~-agonist; FDC, fixed-dose combination; CI, confidence interval; DPI, dry powder inhaler; pMDI, pressurized metered-dose inhaler; COPD, chronic obstructive pulmonary disease.
